デフォルト表紙
市場調査レポート
商品コード
1732824

細胞・遺伝子治療バイオ分析試験サービス市場- 世界の産業規模、シェア、動向、機会、予測、試験タイプ別、製品タイプ別、開発段階別、適応症別、地域別、競合別、2020-2030年

Cell & Gene Therapy Bioanalytical Testing Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Product Type, By Stage of Development, By Indication, By Region and Competition, 2020-2030F


出版日
ページ情報
英文 182 Pages
納期
2~3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

細胞・遺伝子治療バイオ分析試験サービス市場- 世界の産業規模、シェア、動向、機会、予測、試験タイプ別、製品タイプ別、開発段階別、適応症別、地域別、競合別、2020-2030年
出版日: 2025年05月23日
発行: TechSci Research
ページ情報: 英文 182 Pages
納期: 2~3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

細胞・遺伝子治療バイオ分析試験サービスの世界市場は、2024年には5億2,326万米ドルと評価され、2030年には8億7,029万米ドルに達すると予測され、予測期間中のCAGRは8.85%で成長する見込みです。

拡大する細胞・遺伝子治療分野は、個別化された標的治療を提供することで、遺伝性疾患や慢性疾患の治療アプローチに革命をもたらしています。これらの治療が研究から商業化へと進むにつれて、精密で準拠性の高い生物学的分析試験サービスへの需要が著しく高まっています。これらのサービスは、進化する規制の期待に沿った安全性、有効性、品質を確保するために不可欠です。支援資金、技術革新、および治療パイプラインの拡大が市場開拓を加速している一方で、オーダーメイドの治療ソリューションを重視する業界の高まりが、細胞・遺伝子治療のライフサイクルにおけるバイオ分析検査の役割を高め続けています。

市場概要
予測期間 2026-2030
市場規模:2024年 5億2,326万米ドル
市場規模:2030年 8億7,029万米ドル
CAGR:2025年~2030年 8.85%
急成長セグメント 腫瘍学
最大市場 北米

市場促進要因

細胞・遺伝子治療の研究開発投資の増加

主な市場課題

規制上の課題

主要市場動向

技術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の細胞・遺伝子治療バイオ分析試験サービス市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 試験の種類別(バイオアベイラビリティおよび生物学的同等性試験、薬物動態、薬力学、その他の試験の種類)
    • 製品タイプ別(遺伝子治療、遺伝子改変細胞治療、細胞治療)
    • 開発段階別(非臨床、臨床)
    • 適応症別(腫瘍学、感染症、神経疾患、希少疾患、その他)
    • 地域別
    • 企業別(2024)
  • 市場マップ

第6章 北米の細胞・遺伝子治療バイオ分析試験サービス市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米:国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の細胞・遺伝子治療バイオ分析試験サービス市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州:国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域の細胞・遺伝子治療バイオ分析試験サービス市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域:国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の細胞・遺伝子治療バイオ分析試験サービス市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米:国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの細胞・遺伝子治療バイオ分析試験サービス市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ:国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品開発
  • 最近の動向

第13章 世界の細胞・遺伝子治療バイオ分析試験サービス市場:SWOT分析

第14章 競合情勢

  • BioAgilytix Labs Inc.
  • KCAS Bioanalytical & Biomarker Services
  • IQVIA, Inc.
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Prolytix pvt ltd
  • Pharmaron Biologics(UK)Ltd
  • Charles River Laboratories International, Inc.
  • Syneos Health Ltd
  • Intertek Group Plc

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 16278

The Global Cell & Gene Therapy Bioanalytical Testing Services Market was valued at USD 523.26 million in 2024 and is expected to reach USD 870.29 million by 2030, growing at a CAGR of 8.85% during the forecast period. The expanding field of cell and gene therapy is revolutionizing treatment approaches for genetic and chronic diseases by offering personalized, targeted therapies. As these therapies progress from research to commercialization, the demand for precise and compliant bioanalytical testing services is growing significantly. These services are critical for ensuring safety, efficacy, and quality in line with evolving regulatory expectations. Supportive funding, technological innovations, and the expanding therapeutic pipeline are accelerating market development, while growing industry emphasis on tailored treatment solutions continues to elevate the role of bioanalytical testing in the cell and gene therapy lifecycle.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 523.26 Million
Market Size 2030USD 870.29 Million
CAGR 2025-20308.85%
Fastest Growing SegmentOncology
Largest MarketNorth America

Key Market Drivers

Increasing Investment in Cell and Gene Therapy Research and Development

Recent breakthroughs in cell and gene therapy have opened new possibilities for treating diseases previously deemed untreatable. These treatments work by altering patients' own cells or genes to address conditions such as cancer, autoimmune disorders, and genetic abnormalities. As the clinical potential of these therapies becomes more evident, global investment in research and development has increased rapidly. Bioanalytical testing services play an essential role in this growth by ensuring product safety, efficacy, and consistency. Notably, in April 2023, the California Institute for Regenerative Medicine committed USD 89.0 million toward advancing gene and stem cell research, exemplifying the growing commitment to innovation in this space.

Key Market Challenges

Regulatory Challenges

Navigating regulatory frameworks remains one of the most pressing challenges in the cell and gene therapy bioanalytical testing market. Regulatory agencies are continuously updating standards to ensure patient safety while accommodating rapid technological advances. This dynamic landscape makes compliance a complex and time-consuming process. Companies often face delays and increased costs when attempting to align with these evolving guidelines, which can hinder the pace of therapy development and market entry. Meeting global regulatory expectations while innovating at speed demands significant investment and specialized expertise.

Key Market Trends

Technological Advancements

As cell and gene therapies reshape modern medicine, the bioanalytical testing segment is advancing rapidly to meet new analytical demands. A major trend is the integration of single-cell analysis technologies, including single-cell RNA sequencing and proteomics, which allow deeper insights into cellular responses and therapeutic outcomes. These methods address the limitations of traditional bulk analysis by revealing intercellular variability. Another transformative trend is the adoption of CRISPR-Cas9, a powerful gene-editing tool that demands specialized testing protocols to evaluate gene function and detect potential off-target effects. Furthermore, the deployment of state-of-the-art instrumentation has enhanced the precision and speed of testing processes, enabling faster and more accurate evaluation of complex therapies and supporting the broader growth of the market.

Key Market Players

  • BioAgilytix Labs Inc.
  • KCAS Bioanalytical & Biomarker Services
  • IQVIA, Inc.
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Prolytix pvt ltd
  • Pharmaron Biologics (UK) Ltd
  • Charles River Laboratories International, Inc.
  • Syneos Health Ltd
  • Intertek Group Plc

Report Scope:

In this report, the Global Cell & Gene Therapy Bioanalytical Testing Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell & Gene Therapy Bioanalytical Testing Services Market, By Test Type:

  • Bioavailability & Bioequivalence Studies
  • Pharmacokinetics
  • Pharmacodynamics
  • Other test type

Cell & Gene Therapy Bioanalytical Testing Services Market, By Product Type:

  • Gene Therapy
  • Gene-Modified Cell Therapy
  • Cell Therapy

Cell & Gene Therapy Bioanalytical Testing Services Market, By Stage of Development:

  • Non-Clinical
  • Clinical

Cell & Gene Therapy Bioanalytical Testing Services Market, By Indication:

  • Oncology
  • Infectious Diseases
  • Neurological disorders
  • Rare Diseases
  • Others

Cell & Gene Therapy Bioanalytical Testing Services Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell & Gene Therapy Bioanalytical Testing Services Market.

Available Customizations:

Global Cell & Gene Therapy Bioanalytical Testing Services market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

4. Voice of Customer

5. Global Cell & Gene Therapy Bioanalytical Testing Services Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Bioavailability & Bioequivalence Studies, Pharmacokinetics, Pharmacodynamics, Other test Type)
    • 5.2.2. By Product Type (Gene Therapy, Gene-Modified Cell Therapy, Cell Therapy)
    • 5.2.3. By Stage of Development (Non-Clinical, Clinical)
    • 5.2.4. By Indication (Oncology, Infectious Diseases, Neurological disorders, Rare Diseases, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Product Type
    • 6.2.3. By Stage of Development
    • 6.2.4. By Indication
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
        • 6.3.1.2.2. By Product Type
        • 6.3.1.2.3. By Stage of Development
        • 6.3.1.2.4. By Indication
    • 6.3.2. Canada Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
        • 6.3.2.2.2. By Product Type
        • 6.3.2.2.3. By Stage of Development
        • 6.3.2.2.4. By Indication
    • 6.3.3. Mexico Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type
        • 6.3.3.2.2. By Product Type
        • 6.3.3.2.3. By Stage of Development
        • 6.3.3.2.4. By Indication

7. Europe Cell & Gene Therapy Bioanalytical Testing Services Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Product Type
    • 7.2.3. By Stage of Development
    • 7.2.4. By Indication
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
        • 7.3.1.2.2. By Product Type
        • 7.3.1.2.3. By Stage of Development
        • 7.3.1.2.4. By Indication
    • 7.3.2. United Kingdom Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
        • 7.3.2.2.2. By Product Type
        • 7.3.2.2.3. By Stage of Development
        • 7.3.2.2.4. By Indication
    • 7.3.3. Italy Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecasty
        • 7.3.3.2.1. By Test Type
        • 7.3.3.2.2. By Product Type
        • 7.3.3.2.3. By Stage of Development
        • 7.3.3.2.4. By Indication
    • 7.3.4. France Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
        • 7.3.4.2.2. By Product Type
        • 7.3.4.2.3. By Stage of Development
        • 7.3.4.2.4. By Indication
    • 7.3.5. Spain Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type
        • 7.3.5.2.2. By Product Type
        • 7.3.5.2.3. By Stage of Development
        • 7.3.5.2.4. By Indication

8. Asia-Pacific Cell & Gene Therapy Bioanalytical Testing Services Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Product Type
    • 8.2.3. By Stage of Development
    • 8.2.4. By Indication
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
        • 8.3.1.2.2. By Product Type
        • 8.3.1.2.3. By Stage of Development
        • 8.3.1.2.4. By Indication
    • 8.3.2. India Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
        • 8.3.2.2.2. By Product Type
        • 8.3.2.2.3. By Stage of Development
        • 8.3.2.2.4. By Indication
    • 8.3.3. Japan Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
        • 8.3.3.2.2. By Product Type
        • 8.3.3.2.3. By Stage of Development
        • 8.3.3.2.4. By Indication
    • 8.3.4. South Korea Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
        • 8.3.4.2.2. By Product Type
        • 8.3.4.2.3. By Stage of Development
        • 8.3.4.2.4. By Indication
    • 8.3.5. Australia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type
        • 8.3.5.2.2. By Product Type
        • 8.3.5.2.3. By Stage of Development
        • 8.3.5.2.4. By Indication

9. South America Cell & Gene Therapy Bioanalytical Testing Services Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Product Type
    • 9.2.3. By Stage of Development
    • 9.2.4. By Indication
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
        • 9.3.1.2.2. By Product Type
        • 9.3.1.2.3. By Stage of Development
        • 9.3.1.2.4. By Indication
    • 9.3.2. Argentina Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
        • 9.3.2.2.2. By Product Type
        • 9.3.2.2.3. By Stage of Development
        • 9.3.2.2.4. By Indication
    • 9.3.3. Colombia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type
        • 9.3.3.2.2. By Product Type
        • 9.3.3.2.3. By Stage of Development
        • 9.3.3.2.4. By Indication

10. Middle East and Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Product Type
    • 10.2.3. By Stage of Development
    • 10.2.4. By Indication
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
        • 10.3.1.2.2. By Product Type
        • 10.3.1.2.3. By Stage of Development
        • 10.3.1.2.4. By Indication
    • 10.3.2. Saudi Arabia Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
        • 10.3.2.2.2. By Product Type
        • 10.3.2.2.3. By Stage of Development
        • 10.3.2.2.4. By Indication
    • 10.3.3. UAE Cell & Gene Therapy Bioanalytical Testing Services Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type
        • 10.3.3.2.2. By Product Type
        • 10.3.3.2.3. By Stage of Development
        • 10.3.3.2.4. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Global Cell & Gene Therapy Bioanalytical Testing Services Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. BioAgilytix Labs Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. KCAS Bioanalytical & Biomarker Services
  • 14.3. IQVIA, Inc.
  • 14.4. Laboratory Corporation of America Holdings
  • 14.5. Thermo Fisher Scientific Inc.
  • 14.6. Prolytix pvt ltd
  • 14.7. Pharmaron Biologics (UK) Ltd
  • 14.8. Charles River Laboratories International, Inc.
  • 14.9. Syneos Health Ltd
  • 14.10. Intertek Group Plc

15. Strategic Recommendations

16. About Us & Disclaimer